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ABSTRACT
Purpose The objectives of the International epidemiology 
databases to evaluate AIDS (IeDEA) are to (i) evaluate the 
delivery of combination antiretroviral therapy (ART) in 
children, adolescents and adults in sub- Saharan Africa, 
(ii) to describe ART regimen effectiveness, durability and 
tolerability, (iii) to examine HIV- related comorbidities and 
coinfections and (iv) to examine the pregnancy- related and 
HIV- related outcomes of women on ART and their infants 
exposed to HIV or ART in utero or via breast milk.
Participants IeDEA is organised in four regions (Central, 
East, Southern and West Africa), with 240 treatment and 
care sites, six data centres at African, European and US 
universities, and almost 1.4 million children, adolescents 
and adult people living with HIV (PLWHIV) enrolled.
Findings to date The data include socio- demographic 
characteristics, clinical outcomes, opportunistic 
events, treatment regimens, clinic visits and laboratory 
measurements. They have been used to analyse outcomes 
in PLWHIV-1 or PLWHIV-2 who initiate ART, including 
determinants of mortality, of switching to second- line 
and third- line ART, drug resistance, loss to follow- up and 
the immunological and virological response to different 
ART regimens. Programme- level estimates of mortality 
have been corrected for loss to follow- up. We examined 
the impact of coinfection with hepatitis B and C, and 
the epidemiology of different cancers and of (multidrug 
resistant) tuberculosis, renal disease and of mental illness. 
The adoption of ‘Treat All’, making ART available to all 
PLWHIV regardless of CD4+ cell count or clinical stage was 
another important research topic.
Future plans IeDEA has formulated several research 
priorities for the ‘Treat All’ era in sub- Saharan Africa. 
It recently obtained funding to set up sentinel sites 
where additional data are prospectively collected on 
cardiometabolic risks factors as well as mental health and 
liver diseases, and is planning to create a drug resistance 
database.
InTRoduCTIon
The roll- out of combination antiretroviral 
therapy (ART) in sub- Saharan Africa from 
2004 onwards has substantially improved the 
prognosis of HIV-1 infection, with a decline 
in AIDS- related deaths1 and a decline in the 
incidence of new HIV-1 infections.2 However, 
in many settings, HIV/AIDS is still a public 
health threat. An estimated 1.8 million new 
infections occurred in 2017 and almost a 
million adult and child deaths were due to 
HIV, most of them in sub- Saharan Africa.2
The WHO, the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) and 
many of the countries most heavily affected 
by the HIV epidemic have committed to 
ending HIV/AIDS as a major public health 
problem by 2030.1 Targets to be reached by 
2020 include that 90% of people living with 
Strengths and limitations of this study
 ► An important strength of the International epide-
miology databases to evaluate AIDS (IeDEA) cohort 
collaboration in sub- Saharan Africa is its large size, 
which allows analyses of outcomes of antiretroviral 
therapy (ART) in children, adolescents and pregnant 
and postpartum women, across diverse settings.
 ► The data reflect routine care across a wide range of 
real- world settings during the scale up of ART in sub- 
Saharan Africa and thus provide a valuable platform 
to conduct operational and clinical research and to 
study temporal trends and the impact of changes in 
guidelines and other interventions.
 ► The development of a standardised Data Exchange 
Standard protocol has contributed to increase data 
quality, and data have been enriched by linkage to 
cancer registries, vital registries and administrative 
databases.
 ► Collaborations with the WHO, United Nations 
Programme on AIDS, the mathematical modelling 
community and other consortia have ensured that 
the analyses of the African IeDEA regions contribut-
ed to global health policy and decision- making.
 ► Weaknesses include the limitations inherent in sec-
ondary use of routine clinical care data, with missing 
data, the lack of standardised follow- up visits and 
substantial loss to follow- up resulting in unknown 
outcome.
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Figure 1 Map of the 240 active facilities participating in the four African regions of the International epidemiology Databases to 
Evaluate AIDS (A), together with cumulative numbers of patients starting antiretroviral therapy (B).
HIV (PLWHIV) be aware of their status, 90% of those 
diagnosed initiate ART and 90% of those on ART achieve 
undetectable viral loads (the 90-90-90 targets).3 Progress 
towards these goals has been more substantial in Eastern 
and Southern Africa than in West and Central Africa. Of 
the 20.6 million PLWHIV in Eastern and Southern Africa, 
an estimated 58% were virally suppressed, compared with 
39% of 5.0 million in West and Central Africa.4
Established more than 10 years ago by the National 
Institutes of Health (NIH), the International epidemi-
ology databases to evaluate AIDS (IeDEA) are a global 
cohort collaboration that collects HIV/AIDS data from 
HIV care and treatment programmes, including in sub- 
Saharan Africa. The regional IeDEA data centres consoli-
date, curate and analyse data to evaluate the outcomes of 
PLWHIV/PLWAIDS and monitor progress. The first years 
of the cohorts in sub- Saharan Africa were described previ-
ously;5 here we provide an update on methods, key data 
and future plans.
CohoRT deSCRIPTIon
In 2006, the National Institute of Allergy and Infectious 
Diseases sought applications for a global consortium struc-
tured through regional centres to pool clinical and epide-
miological data on PLWHIV, in order to address questions 
that could not be answered by individual cohorts.5 IeDEA 
covers seven geographic regions, namely North America, 
the Caribbean and Central/South America, the Asia- 
Pacific and four regions in sub- Saharan Africa: West 
Africa, Central Africa, East Africa and Southern Africa. 
The project was initially funded for a 5- year period and 
has since been extended twice, with the current funding 
cycle ending in 2021.
Settings and number of PLWhIV enrolled
To date, the African regions of IeDEA received data from 
240 HIV care and treatment facilities in 19 sub- Saharan 
African countries (figure 1A). Close to 1 400 000 PLWHIV 
who initiated ART in sub- Saharan Africa are included 
(figure 1B), of whom over 680 000 are currently in care. 
In East and Southern Africa, both urban and rural facili-
ties are well represented, while in Central and West Africa, 
urban facilities dominate. Facilities are predominately 
public (94%) and operated at the primary or secondary 
care level, with the exception of West Africa where 70% of 
facilities are at the tertiary level of care (table 1).
data collection at individual and site level
Since its inception, IeDEA has collected routine clin-
ical data of PLWHIV followed under treatment, which 
includes sociodemographic characteristics, clinical 
outcomes, opportunistic events, treatment regimens, 
clinic visits and laboratory measurements. More recently, 
the IeDEA network has developed a Data Exchange Stan-
dard protocol (see www. iedeades. org) with 25 data tables, 
which include a total of 228 unique variables (36 compul-
sory and 192 additional variables) and within- region 
unique patient research identifiers. Standardised data 
collection is supported by eight codebooks, including the 
Anatomical Therapeutic Chemical (ATC) classification 
for drugs and lists with codes for reasons for stopping 
treatment, for dropping out of the cohort, for mode of 
HIV infection, country, type and site of comorbidities, 
laboratory measurements and units of measurements and 
type of viral load assay. The collection, management and 
sharing of data is facilitated by the Harmonist toolkit, a 
software and standards package that supports research 
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Table 1 Characteristics of 240 facilities providing ART in the African regions of the IeDEA (source: site assessment survey 
2017 and IeDEA database 2019)
West Africa Central Africa East Africa Southern Africa All regions (%)
No. of active facilities 17 19 72 132 240
No. of patients on ART 45 015 32 754 252 266 1 066 591 1 396 626
  Location
  Urban 17 19 19 65 120 (50)
  Rural 0 0 52 67 119 (50)
  Missing 0 0 1 0 1 (0)
Level of care
  Primary 4 12 49 107 172 (72)
  Secondary 1 0 16 20 37 (15)
  Tertiary 12 7 6 5 30 (13)
  Missing 0 0 1 0 1 (0)
Type of facility
  Public 12 16 69 128 225 (94)
  Private 2 3 3 4 12 (5)
  Missing 3 0 0 0 3 (1)
Viral load
  Routine testing 12 16 46 74 148 (62)
  Tests performed onsite 8 6 4 3 21 (9)
  Tests performed offsite 6 13 53 127 199 (83)
CD4 monitoring
  Routine testing 14 6 9 97 126 (53)
  Tests performed onsite 11 8 23 51 93 (39)
  Tests performed offsite 3 11 35 71 120 (50)
HIV-1 genotypic drug resistance
  Routine testing 2 2 10 48 62 (26)
Routine tracing of patients lost 
to follow- up
  Yes 13 19 56 93 181 (75)
  No 1 0 1 37 39 (16)
  Missing 3 0 15 2 20 (8)
Tracing method*
  Phone 14 18 57 110 199 (83)
  Text message/mail/email 2 2 10 14 28 (15)
  Home visit 9 17 52 129 207 (86)
Medication disruption/stock 
outs over last 12 months
  First- line ART 5 2 20 32 59 (25)
  Second- line ART 5 6 18 16 45 (19)
*Sites may use more than one method.
ART, antiretroviral therapy; IeDEA, International epidemiology Databases to Evaluate AIDS.
projects through the Research Electronic Data Capture 
(REDCap) system.6
In recent years, site assessments and site surveys have 
been conducted on a regular basis to collect up- to- date 
information related to available clinical service and care 
models in the participating facilities. For example, a 
study compared the characteristics and comprehensive-
ness of adult HIV care and treatment programmes in 
sub- Saharan Africa with programmes in the Americas 
and Asia- Pacific region.7 Other studies examined the 
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management of mental health and substance use disor-
ders,8 or the diagnostic and screening practices for (drug 
resistant) tuberculosis in adult and paediatric patients.9–11 
Furthermore, the routine data collected by participating 
sites have been enriched in some countries by linking the 
HIV databases to cancer registries,12 13 vital registries14 or 
administrative databases.15
Trends in Cd4 cell count and viral load measurements
While WHO continues to recommend a CD4 cell count 
before starting ART to inform the management of 
advanced disease and differentiated care in the Treat 
All era, it also recommends that CD4 testing be replaced 
by viral load measurement for monitoring of treatment 
and identification of treatment failure.16 Figure 2 shows 
that in Southern and West Africa, the number of CD4 
measurements tended to be stable over time, despite 
an increasing number of PLWHIV in care, while in East 
and Central Africa, the number of CD4 measurements 
dropped. At present, 53% of the active facilities reported 
routine CD4 testing and 62% routine viral load testing 
(table 1). The US President’s Emergency Plan for AIDS 
Relief, which provides substantial funding for AIDS treat-
ment, care and prevention in countries most affected by 
the epidemic, has progressively reduced its support for 
CD4 testing.17
Trends in ART
Until recently, the recommended first- line ART regimen 
in sub- Saharan Africa consisted of two nucleoside reverse 
transcriptase inhibitors and one non- nucleoside reverse 
transcriptase inhibitor (2NRTIs+1NNRTI). The combina-
tion of tenofovir (TDF), lamivudine (3TC) (or emtricit-
abine (FTC)) and efavirenz (EFV) is the current treatment 
of choice. The phasing out of stavudine (D4T) and nevi-
rapine (NVP) was almost complete in 2014 (table 2). 
East Africa and Southern Africa are currently rolling out 
dolutegravir, an integrase inhibitor with a high barrier to 
resistance.18 19 Due to concerns about an increased risk 
of neural tube defects if taken during pregnancy,20 the 
roll- out to women has been delayed or limited in some 
settings. Of note, drug stock- outs in the last 12 months 
were reported by 59 facilities for first- line drugs, and by 
45 for second- line drugs (table 1).
Mortality and retention in care
In cohorts of PLWHIV who initiated ART in consec-
utive 2- year periods from 2001 to 2016, mortality at 3 
years declined substantially in all African IeDEA regions 
(figure 3A). Loss to follow- up, defined as more than 90 
days late to the next scheduled visit, remained substantial 
in all regions, and particularly high in Southern Africa 
(figure 3B). Retention in care is key to the success of 
the public health approach to ART. Loss to follow- up 
has been an important issue for IeDEA, and activities to 
trace PLWHIV not returning to the clinic have increased 
in recent years. At present, tracing of PLWHIV on ART 
who were lost to follow- up is in place in 89% of the active 
facilities; 75% have implemented it routinely (table 1). 
Tracing methods vary widely across facilities and include 
phone calls and home visits by clinic staff or community 
health workers.
Patient and public involvement
IeDEA is based on the collection of routine clinical data 
and no patients were involved in developing the research 
question, outcome measures and overall design of the 
collaboration. Due to the anonymous nature of the data, 
we cannot disseminate the results of analyses of the data 
directly to study participants.
FIndIngS To dATe
Over 500 publications in MEDLINE acknowledge funding 
from a core grant from the NIH to one or several African 
IeDEA regions, and these publications have been cited 
over 10 000 times. Multiregional projects are developed 
in IeDEA working groups, which currently address eight 
clinical areas: (i) cancer, (ii) ART outcomes, (iii) hepatitis, 
(iv) mental health, (v) mother–infant and paediatrics, 
(vi) renal disease, (vii) substance use and (viii) tubercu-
losis. Multiregional research concepts are discussed in 
the Executive Committee of IeDEA, revised and approved 
or rejected. In recent years, several analyses were done 
in collaboration with WHO or UNAIDS.21–23 The number 
of publications reporting multiregional analyses from 
several African IeDEA regions increased over time, from 
one such publication in 2007 to 24 multiregional publi-
cations in 2018. Some of the key studies are summarised 
below, with a focus on more recent and on multiregional 
analyses.
Treatment outcomes in adults, adolescents, children and 
pregnant women
Several studies examined outcomes in PLWHIV-1 or 
PLWHIV-2 who initiate ART, including determinants of 
mortality, of switching to second- line and third- line ART, 
drug resistance, loss to follow- up and the immunological 
and virological response to different ART regimens.24–37 
For example, the African IeDEA regions contributed 
importantly to a large- scale analysis of outcomes in 
adolescents living with perinatally acquired HIV, which 
showed that HIV- associated mortality during adolescence 
was substantially higher in sub- Saharan Africa, South and 
Southeast Asia, and South America and the Caribbean 
than in Europe.36 A similar analysis of adolescents living 
with HIV showed that mortality and loss to follow- up were 
worse among those entering care at 15 years or older.37 
The authors concluded that adolescents must be eval-
uated separately from younger children and adults to 
identify population- specific reasons for death and loss to 
follow- up.37
Programme-level mortality
It became clear early on during the scale- up of ART in sub- 
Saharan Africa, that loss to follow- up of patients initiating 
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Figure 2 Daily number of CD4 cell counts and viral load (VL) measurements over time (bar chart) and the number of patients in 
care (red line).
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Figure 3 Trends in mortality (A) and loss to follow (B), 2001 
to 2016. ART, antiretroviral therapy.
ART was substantial,38 and that mortality among patients 
lost was higher than among patients remaining in care.39 
Ignoring loss to follow- up might thus bias programme- 
level estimates of mortality, and much effort has gone 
into correcting programme- level mortality for loss to 
follow- up.40–46 For example, an analysis of all four African 
regions showed that when analysing the uncorrected data 
observed in the clinics, 52% of adults and children were 
retained on ART, 42% were lost to follow- up and 6% had 
died 5 years after ART initiation.46 After accounting for 
undocumented deaths and self- transfers, an estimated 
67% of patients were retained on ART, 19% had stopped 
ART and 15% had died.46
Coinfections and comorbidities
IeDEA investigators have examined the prevalence and 
impact of coinfection with hepatitis B and C, and the 
epidemiology of different cancers and of (multidrug 
resistant) tuberculosis, renal disease and of mental 
illness.8 47–58 For example, an analysis of IeDEA data and 
data from the Collaboration of Observational HIV Epide-
miological Research in Europe (COHERE)59 showed that 
children living with HIV from sub- Saharan Africa, but 
not those from Europe or Asia had a high risk of devel-
oping Kaposi sarcoma after starting ART.58 Similarly, a 
recent analysis of IeDEA and COHERE data showed that 
compared with European women, rates of cervical cancer 
were 11 times higher in South Africa.50 A recent multire-
gional study of multidrug resistant tuberculosis included 
HIV- positive and HIV- negative adults with tuberculosis 
from seven high- burden countries (Côte d'Ivoire, Demo-
cratic Republic of the Congo, Kenya, Nigeria, South 
Africa, Peru and Thailand). Molecular or phenotypic 
drug susceptibility testing was done locally and at a refer-
ence laboratory. The results showed that inaccurate local 
drug susceptibility testing led to undertreatment of drug- 
resistant tuberculosis and increased mortality.54
Challenge of ‘Treat All’
Nearly all countries in sub- Saharan Africa have now 
adopted national polices to offer ART to all PLWHIV 
regardless of CD4 cell count or clinical stage (‘Treat All’), 
in order to meet the UNAIDS 90-90-90 targets. In 2011, 
Malawi was one of the first countries to implement such 
a strategy for the prevention of mother- to- child transmis-
sion, recommending ART for pregnant and breastfeeding 
women living with HIV, regardless of CD4 cell count or 
WHO clinical stage (‘Option B+’). An IeDEA analysis of 
the Malawian experience showed that poor retention in 
care was a problem in many facilities, with early loss to 
follow- up particularly high in facilities with a high patient 
volume and in patients who start ART during pregnancy 
on the day of HIV diagnosis.35 More recently, IeDEA inves-
tigators used regression discontinuity analysis to examine 
changes in rapid HIV treatment initiation after national 
‘Treat All’ policy adoption in six countries (Burundi, 
Kenya, Malawi, Rwanda, Uganda and Zambia).60 They 
showed a strong and sustained effect of the adoption of 
‘Treat All’ policies on ART initiation within 30 days of 
enrollment in HIV care in all six countries.60
Future plans
At the end of 2018, IeDEA published a consensus state-
ment61 and a journal supplement62 on research priorities 
to inform the implementation of the ‘Treat All’ policy in 
children and adolescents,63 pregnant and postpartum 
women,64 and for mental health, substance use65 and drug 
resistance.66 These documents will guide IeDEA’s future 
research agenda in sub- Saharan Africa. Furthermore, 
the creation of an IeDEA Sentinel Research Network will 
facilitate the collection of detailed data in selected IeDEA 
sites on cardiometabolic risk factors (eg, hypertension, 
diabetes and dyslipidaemia) liver disease (liver fibrosis 
and steatosis), mental health and substance use. In the 
East and Southern African regions, pharmacovigilance in 
pregnancy is being developed to assess the impact of ART 
on birth outcomes. A project involving all four African 
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regions studies the cascade of screening for cervical 
cancer, while the establishment of the South African HIV 
Cancer Match (SAM) study of over 10 million PLWHIV, 
from linkage of national laboratory with cancer registry 
data, will allow the study of less common cancers. Finally, 
the creation of a drug resistance database as a central 
repository for resistance tests performed in routine clin-
ical care is another planned addition.
CoLLABoRATIonS
The African regions of IeDEA have collaborated and 
continue to encourage collaborations with other 
consortia, cohort collaborations, the HIV modelling 
community and public health agencies as well as indi-
viduals wishing to use IeDEA data. Examples include 
work with COHERE,50 58 67 68 the Collaborative Initiative 
for Paediatric HIV Education and Research36 69 or the 
Measurement and Surveillance of HIV Epidemics consor-
tium22 as well as UNAIDS22 23 and WHO.21 Further collab-
orations are welcome. Investigators wishing to work with 
the IeDEA data should contact the teams at the regional 
data centres (see www. iedea. org for contact details) and 
send a concept sheet for the analyses they are interested 
in performing and the variables that would be required. 
Anyone wishing to work with IeDEA must sign a data- use 
agreement.
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